Ulinastatin, a Urinary Trypsin Inhibitor, for the Initial Treatment of Patients With Kawasaki Disease | Zendy

Takashi Kanai | Zendy; Takahiro Ishiwata | Zendy; Tohru Kobayashi | Zendy; Hiroki Sato | Zendy; Mari Takizawa | Zendy; Yoichi Kawamura | Zendy; Hiroshi Tsujimoto | Zendy; Keigo Nakatani | Zendy; Naoko Ishibashi | Zendy; Mitsunori Nishiyama | Zendy; Yoshiho Hatai | Zendy; Yuh Asano | Zendy; Tomio Kobayashi | Zendy; S Takeshita | Zendy; Shigeaki oyama | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ulinastatin, a Urinary Trypsin Inhibitor, for the Initial Treatment of Patients With Kawasaki Disease

Author(s) -

Takashi Kanai,

Takahiro Ishiwata,

Tohru Kobayashi,

Hiroki Sato,

Mari Takizawa,

Yoichi Kawamura,

Hiroshi Tsujimoto,

Keigo Nakatani,

Naoko Ishibashi,

Mitsunori Nishiyama,

Yoshiho Hatai,

Yuh Asano,

Tomio Kobayashi,

S Takeshita,

Shigeaki oyama

Publication year - 2011

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.111.028423

Subject(s) - medicine , ulinastatin , kawasaki disease , aspirin , odds ratio , confidence interval , gastroenterology , urinary system , artery

Markedly activated neutrophils or higher plasma levels of neutrophil elastase are involved in the poor response to intravenous immunoglobulin (IVIG) and the formation of coronary artery lesions (CAL) in patients with acute Kawasaki disease. We hypothesized that ulinastatin (UTI), by both direct and indirect suppression of neutrophils, would reduce the occurrence of CAL.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research